-
Company Profile
![]()
OncoSec Medical Inc – Company Profile
OncoSec Medical Inc (OncoSec) is a biotechnology company that focusses on designing and developing gene therapies, therapeutics, and medical approaches. It offers services to stimulate body’s immune system and attack cancer. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company also identifies and develops novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s MK-8189
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Chronic Lymphocytic Leukemia (CLL) Drug Details: Nemtabrutinib (ARQ-531) is under development for the...
-
Product Insights
OncoSec Medical Inc Pipeline Insight and Competitive Landscape, 2023
OncoSec Medical Inc (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company is also identifying and developing novel immune-targeting agents for use with the immunogenicity platform....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – NIS-793 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nisevokitug in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details: Nisevokitug (NIS-793) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tavokinogene Telseplasmid in Metastatic Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Tavokinogene Telseplasmid in Metastatic Melanoma Drug Details:Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) is under development for the...
-
Thematic Analysis
![]()
Precision and Personalized Medicine in Pharma – Thematic Intelligence
Precision and Personalized Medicine in Pharma Thematic Report Overview Precision and personalized medicine have already begun to reshape disease treatment paradigms and the provision of healthcare. Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space. The precision and personalized medicine in pharma thematic intelligence report provides a focused chapter on the key healthcare, technology,...
-
Sector Analysis
![]()
Immuno-oncology (IO) – Thematic Intelligence
Accessing the in-depth insight from the ‘Immuno-Oncology Market' report will allow you to – Obtain immuno-oncology market assessment and forecast across multiple regions Gain insight into promising early-stage approaches. Our indication specific forecast models answer questions such as – What is the target patient pool for cell & gene therapies in each cancer indication? Which patient groups are more likely to receive these therapies? What does the cell & gene therapy clinical stage pipeline look like in each cancer indication What...
-
Product Insights
Merkel Cell Carcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Merkel Cell Carcinoma Pipeline Drugs Market Report Overview Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Symptom includes painless nodule on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery. The Merkel Cell Carcinoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Merkel Cell...
-
Product Insights
![]()
Net Present Value Model: TAVO
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TAVO Drug Details Tavokinogene telseplasmid (DNA...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – tavokinogene telseplasmid
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tavokinogene telseplasmid Drug Details Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) is under development for the...
-
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Head and Neck Cancer Pipeline Drugs Market Report Overview Head and Neck Cancer symptoms include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. Treatment includes chemotherapy and radiation therapy. The Head and Neck Cancer pipeline drugs market research report provides an analysis of the Head and Neck Cancer drugs by stage of development, drug target, mechanism of action (MoA), route...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Inhalable Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
An inhalable drug delivery device is meant to administer medications that are to be inhaled deeply into the lungs. Drugs are delivered either by the nasal or oral respiratory route. The Inhalable Drug Delivery Pipeline market research report provides comprehensive information about the inhalable drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Sector Analysis
Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines
The bio/pharmaceutical industry is experiencing a shortage of viral vectors, a component needed to produce gene therapies and gene-modified cell therapies, as well as certain COVID-19 vaccines that require a viral vector, notably those from AstraZeneca and Johnson & Johnson (J&J). This report reveals that viral vector production is limited by insufficient manufacturing capacity, an inefficient manufacturing process, and the requirement for complex specialist facilities. There are 14 therapies/vaccines that use a viral vector (gene therapies, gene-modified cell therapies, and...
-
Sector Analysis
Melanoma – Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body. Although melanoma has high survivability, it remains a significant health risk around the world. Where possible, melanoma is treated with surgery, with stage III patients likely to receive adjuvant therapy with either PD-1 inhibitors; BMS’ Opdivo or Merck & Co’s Keytruda or, if BRAF V600-positive, Novartis’ BRAF/MEK inhibitor combination Tafinlar + Mekinist. Metastatic...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Track & Monitor
Gene Therapy Market Opportunity For CMOs – 2019 PharmSource Edition
This report will explore whether the bio/pharma industry is adequately prepared for future gene therapy developments and whether CDMOs are making appropriate investments in the capacity and technology to support the coming opportunity.
-
Sector Analysis
Gene Therapy in Oncology
Unlike conventional treatments such as chemotherapy, gene therapy combines reduced treatment duration (one time treatment in some cases) with higher chances of cure in oncology. This novel therapeutic approach requires direct delivery of genetic material to the patient or in vitro genetic modification of patient cells and subsequent delivery to the patient, which is an uncharted territory in oncology and will necessitate the implementation of new regulatory guidelines and restructuring of the existing treatment algorithms in various oncology indications. In...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.